18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
ConditionPheochromocytoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorFirst Affiliated Hospital of Zhejiang University
About this trial
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Eligibility criteria
Qualifiers
Aged 30-80 years old, primary school or above, with a regular caregiver;
Clinically diagnosed patients with pheochromocytoma;
Can provide informed consent, can understand and comply with the study requirements.
Disqualifiers
Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;
Uncontrolled hypertension or high-risk BP (i.e., systolic BP > 180 mmHg or diastolic BP > 110 mmHg);
Patients with mental disorders or primary affective disorders;
Unable to understand and adhere to the study protocol or provide informed consent;
Trial design
Treatments tested in this trial
- 18F-MFBG
Treatment groups
80 Participants
are divided into 1 treatment groupLocations
2The First Affiliated Hospital of Zhejiang University School of Medicine310003, HangzhouZhejiang, China
The First Affiliated Hospital Zhejiang University School of Medicine310006, HangzhouZhejiang, China
Sponsors and collaborators
First Affiliated Hospital of Zhejiang University
Lead sponsor
Source ClinicalTrials.gov